ArticleNeuroscience letters2007
Cholesterol level, statin use and Alzheimer's disease in adults with Down syndrome.
Article in Neuroscience letters, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 3 syntheses or guidelines pooled it, 47 citations in OpenAlex.
- Association of Alzheimer Disease With Life Expectancy in People With Down Syndrome.JAMA network open · 2022Pooled it
- Use of statins and the risk of dementia and mild cognitive impairment: A systematic review and meta-analysis.Scientific reports · 2018Pooled it
- Lipid-lowering Drugs and Neurocognitive Function: A Systematic Review.In vivo (Athens, Greece)Pooled it
- Trial
- Trial
- A neuropathology case report of a woman with Down syndrome who remained cognitively stable: Implications for resilience to neuropathology.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025Article
- Obesity, diabetes and their metabolic correlates in middle-aged adults with Down syndrome.Journal of intellectual disability research : JIDR · 2024Article
- Risk of New-Onset Dementia in Patients with Chronic Kidney Disease on Statin Users: A Population-Based Cohort Study.Biomedicines · 2023Article
- Review
- The Clinical and Neuropathological Features of Sporadic (Late-Onset) and Genetic Forms of Alzheimer's Disease.Journal of clinical medicine · 2021Review
- Article
- The Alzheimer's Biomarker Consortium-Down Syndrome: Rationale and methodology.Alzheimer's & dementia (Amsterdam, Netherlands) · 2020Review
- Candidate gene analysis for Alzheimer's disease in adults with Down syndrome.Neurobiology of aging · 2017Article
- A genetic cause of Alzheimer disease: mechanistic insights from Down syndrome.Nature reviews. Neuroscience · 2015Review
- Statin Use, Incident Dementia and Alzheimer Disease in Elderly African Americans.Ethnicity & disease · 2015Article
- Serum lipids are related to Alzheimer's pathology in nursing home residents.Dementia and geriatric cognitive disorders · 2009Article
- L-arginine and Alzheimer's disease.International journal of clinical and experimental pathology · 2009Article
- Alzheimer's Disease in Adults with Down Syndrome.International review of research in mental retardation · 2008Article
- Tamarindus indica seeds improve carbohydrate and lipid metabolism: An in vivo study.Journal of Ayurveda and integrative medicineArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 4 institutions in 1 country.
Funding
Abstract
Adults with Down syndrome (DS) are at significantly higher risk of Alzheimer's disease (AD) than the general population, but there is considerable variability in age at onset. This study tested the hypothesis that total cholesterol (TC) levels are related to vulnerability, and that the use of statins may decrease risk. The relation of TC level and statin use to risk of AD was investigated in 123 Caucasian adults with DS. Evaluations included serial assessments of cognitive, adaptive and maladaptive behavior, medical records, and neurological examinations. Mean length of follow-up was 5.5 years [1.2-7.1] for the entire sample, 5.1 years [1.2-7.1] for subjects who developed dementia, and 5.6 years [1.5-7.1] for those who did not develop dementia. Controlling for covariates, participants with TC>or=200mg/dL were more than two times as likely to develop AD than subjects with lower TC [hazard rate (HR)=2.59, p=.029, 95% CI: 1.1, 6.1]. In contrast, participants with higher TC levels who used statins during the study, had less than half the risk of developing AD than participants with higher TC levels who did not use statins (HR=.402, p=.095, 95% CI: .138, 1.173). If the protective effects of statins can be further validated, these findings suggest that their use may delay or prevent AD onset in vulnerable populations.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.